MergerLinks Header Logo
Cover Image Amit Sinha
Amit SinhaGOLDMAN SACHS ALTERNATIVES

Amit Sinha

Managing Director and Head of Biotechnology at GOLDMAN SACHS ALTERNATIVES

Investor

Deal Bio

Total Deals4
Valued Deals4
Total Value£6,118M
Avg. Deal Size£1,530M

Sort

United States
Biotechnology
PublicAcquisitionMergerMajority
Avexis

target

Avexis

Novartis

bidder

Novartis

£5,275m

60 dealmakers

Switzerland
Biotechnology
PrivateAcquisitionMajority
Therachon Holding

target

Therachon Holding

Pfizer

bidder

Pfizer

£645m

48 dealmakers

United States
Biotechnology
AcquisitionVenture CapitalCross BorderPrivatePrivate EquityMinority
Moma Therapeutics

target

Moma Therapeutics

Rock Springs Capital

bidder

Rock Springs Capital

£121m

14 dealmakers

United States
Biotechnology
AcquisitionMinorityVenture CapitalDomesticPrivatePrivate Equity
Ajax Therapeutics

target

Ajax Therapeutics

Goldman Sachs Alternatives

bidder

Goldman Sachs Alternatives

£75m

5 dealmakers

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US